Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;127(7):1010-1020.
doi: 10.1002/cncr.33433. Epub 2021 Feb 23.

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies

Zishuo I Hu  1 , Azam Ghafoor  1 , Manjistha Sengupta  1 , Raffit Hassan  1
Affiliations
Review

Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies

Zishuo I Hu et al. Cancer. .

Abstract

Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.

Keywords: chimeric antigen receptor T cells (CAR T cells); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor; immunotherapy; mesothelin; mesothelioma; programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

RH has funding for conduct of clinical trials via a cooperative research and development agreement between NCI and Bayer AG and TCR2 Therapeutics. Other authors do not have any conflict of interests.

References

    1. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17: 525–534. - PubMed
    1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available from URL: https://seer.cancer.gov/csr/1975_2016/.
    1. Amin W, Linkov F, Landsittel DP, et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2018;7: 1184. - PMC - PubMed
    1. Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant Mesothelioma Mortality — United States, 1999–2015. MMWR Morb Mortal Wkly Rep 2017;66:214–218. 2017. - PMC - PubMed
    1. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196: 23–32. - PMC - PubMed

Publication types

MeSH terms